Arrowhead Pharmaceuticals focuses on developing therapies using RNA interference technology to target genes associated with diseases, particularly those with significant unmet medical needs. self-described as aiming to have numerous products in clinical trials or on the market by 2025.

Arrowhead Pharmaceuticals

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Google Tag Manager

Apple Mobile Web Clips Icon

DNSSEC

Google Maps

WordPress

IPv6

Sitelinks Search Box

Healthcare

Javier San Martin

Chief Commercial Officer

Jim Hassard

Chief Financial Officer

Ken Myszkowski

Owner/Founder | Arrowhead Design Company

Lanie Whitaker

Owner

Rick Putney

Deputy General Counsel

Robert Teigen

Chief Commercial Officer (CCO)

Tracie Oliver

Vice President, Clinical Operations

Caroline Laplaca

Vice President, Biology

Christine Esau

Vice President, Plant Management

Dave Bormett

Marianne De Backer

John J. Rossi

Edward W. Frykman

Charles P. McKenney

Lee Hartwell

Mauro Ferrari

Timothy J. Triche

Bruce Given

Chief Operating Officer

Curt Bradshaw

Chief Scientific Officer

James Hassard

Christopher Anzalone

President & CEO

Western US Companies (Top 10K)

Pharmaceutical Public Companies With More Than $10M in Revenue

Pharmaceutical Public Companies With More Than 100 Employees

California Public Companies With Less Than $1B in Revenue

Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Sixth Street

Post-IPO Debt - Arrowhead Pharmaceuticals

Post-IPO Equity - Arrowhead Pharmaceuticals

Silence Therapeutics

OrbiMed

Pasadena

California

United States

North America

Familial Chylomicronemia Syndrome (FCS) Treatment Market Set to Surge at 2.1% CAGR, to Reach $18.32 Mn by 2034

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Key Factors Influencing the 2024 Oligonucleotide Therapy Market: The Rising Cancer Epidemic

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

A technology platform that uses ligand-mediated delivery for tissue-specific targeting in RNAi therapeutics, aiming to simplify manufacturing and reduce costs.

An investigational RNAi therapeutic targeting hypertriglyceridemia by reducing APOC3 protein levels.

An investigational RNAi therapeutic aimed at treating mixed dyslipidemia by targeting ANGPTL3 protein.

An investigational RNAi therapeutic for inflammatory lung diseases, focusing on reducing RAGE protein levels.

An investigational RNAi therapeutic targeting muco-obstructive lung diseases by reducing MUC5AC protein levels.

An investigational RNAi therapeutic for idiopathic pulmonary fibrosis, targeting MMP7 protein.

Germany

Europe

Japan

Asia

China

India

HTML5

Lightbox

Modernizr

Microsoft Outlook

Wordpress

jQuery

Office 365

Adobe Fonts

Vimeo

Google Fonts

Arrowhead Pharmaceuticals owns Visirna Therapeutics

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 23, 2024 9:07 PM	f952e02f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 23, 2024 9:07 PM	cfe60f46
crunchbase trigger	general	Nov 18, 2024 2:12 PM	76fcc8b6
crunchbase profile	general	Nov 18, 2024 4:42 PM	9b6af5ab
li profile	general
translate crunchbase fundingrounds	general	Nov 18, 2024 4:59 PM	704ec790
peers	general	Sep 23, 2024 9:07 PM	938d3e92
news basic	general	Sep 23, 2024 9:07 PM	0f1f3fed
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ARROWHEADPHARMA

Arrowhead Pharmaceuticals